Bone Marrow Transplant Clinical Network

描述（由申请人提供）：宾夕法尼亚大学艾布拉姆森癌症中心（ACC）的骨髓和干细胞移植项目（BMSCTP）是全国最大和最古老的项目之一。这个积极的计划看到所有年龄，性别和种族的患者，并进行各种形式的干细胞移植，包括自体，同种异体，非清髓性和脐带血，匹配和不匹配，相关和不相关的无数疾病。Edward Stadtmauer博士一直是该BMT CTN核心临床中心的PI，也是ACC血液恶性肿瘤项目的联合负责人，因此BMT CTN临床试验的患者准入非常简单，这一点已反映在令人印象深刻的收益中我们的中心。大卫波特博士与Stadtmauer博士密切合作，担任同种异体骨髓移植和免疫治疗主任已有14年。210例患者从Penn累积到BMT CTN;在任何单一中心中，累积人数排名第三。宾夕法尼亚大学的研究人员在网络中表现出了智力领导力; 6个协议团队的成员（2个研究主席）和3个委员会的主席。宾夕法尼亚大学的研究人员是骨髓瘤系列临床试验非常成功的关键。ACC领导了所有3项试验的累积，所有试验均由方案团队领导。宾夕法尼亚大学的BMSCTP在2009年进行的205例干细胞移植中一直非常活跃; 125例自体，80例异体。BMSCTP得到了众多ACC世界级研究资源的支持：我们的研究计划，“他克莫司/MTX与或不与马拉韦罗的III期试验（一种CCR 5抑制剂）作为降低强度异基因干细胞移植后的GVHD预防”是从宾夕法尼亚大学的许多替代方案中选择的，以证明我们的专业领域，基于我们自己的试点研究工作，填补了主要的临床需求，即通过减少GVHD改善同种异体HSCT的结果，并且可以及时完成。强大的临床研究，患者护理，该领域的思想领袖以及BMT CTN试验中记录的热情和成功的这些属性使我们中心能够独特地促进新治疗方法和策略的有效比较，以使血液或骨髓移植受益。 公共卫生相关性：作为BMT CTN核心临床中心的成员资格是ACC BMSCTP的使命的核心，以促进多学科，跨部门和多机构对造血干细胞移植新治疗方法的评估，并将这些发现传播给医疗保健专业人员，患者和公众，以改善患者的预后。

DESCRIPTION (provided by applicant): This Bone Marrow and Stem Cell Transplant Program (BMSCTP) of the University of Pennsylvania Abramson Cancer Center (ACC) is among the largest and oldest in the nation. This active program sees patients of all ages, sexes and ethnic origins and conducts all forms of stem cell transplantation including autologous, allogeneic, non-myeloablative and cord blood, matched and mismatched, related and unrelated for a myriad of diseases. Dr. Edward Stadtmauer has been the PI of this BMT CTN Core Clinical Center and is also the Co-leader of the ACC Hematologic Malignancies Program and so access to patients for BMT CTN clinical trials is straightforward and this has been reflected in the impressive accrual from our center. Dr David Porter works very closely with Dr Stadtmauer and has been the Director of Allogeneic Bone Marrow Transplant and Immunotherapy for 14 years. 210 patients have been accrued from Penn to BMT CTN; the 3rd largest accrual of any single center. Penn investigators have demonstrated intellectual leadership in the Network; membership on 6 protocol teams (study chairs for 2) and chair of 3 committees. Penn investigators were key to the highly successful myeloma series of clinical trials. ACC led accrual in all 3 trials with protocol team leadership in all. Penn's BMSCTP remains consistently very active with 205 stem cell transplants conducted in 2009; 125 autologous, 80 allogeneic. The BMSCTP is supported by numerous ACC world- class research resources: Our research proposal, "A PHASE III TRIAL OF TACROLIMUS/MTX WITH OR WITHOUT MARAVIROC (A CCR5 INHIBITOR) AS GVHD PROPHYLAXIS AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION" was chosen among many alternatives from Penn to demonstrate an area of our expertise, based on our own pilot study work, fill a major clinical need, namely the improvement of outcome for allogeneic HSCT by reducing GVHD, and can be completed in a timely fashion. These attributes of strong clinical research, patient care, thought leaders in the field and a documented enthusiasm and success in BMT CTN trials uniquely position our Center to promote the efficient comparison of novel treatment methods and strategies to benefit blood or marrow transplantation. PUBLIC HEALTH RELEVANCE: Membership as a BMT CTN Core Clinical Center is central to the mission of the ACC BMSCTP to facilitate multidisciplinary, interdepartmental and multi-institutional evaluation of new therapeutic approaches to hematopoietic stem cell transplantation and to disseminate these findings to health care professionals, the patients and the public to improve the outcome of patients.